ION775, a long-acting siRNA targeting APOC3: single-dose, 12-month results in participants with moderate hypertriglyceridemia
Reduction in apolipoprotein C-III (apoC-III) is an established strategy to lower plasma triglycerides (TGs) and TG-rich lipoproteins. To evaluate the safety, tolerability, and pharmacodynamics of ION775, an investigational GalNAc-conjugated small interfering RNA targeting APOC3 messenger RNA, in otherwise...